MATURANA PEREA, ANDRES
Thumbnail Image
Preferred name
MATURANA PEREA, ANDRES
Main Affiliation
Email
amaturana@udd.cl
ORCID
Scopus Author ID
16645817300

Research Output

2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 2014 2014 2013 2013 2012 2012 0.0 0.0 1.0 1.0 2.0 2.0 3.0 3.0 4.0 4.0 5.0 5.0

Filters
13 1
Reset filters

Settings
Now showing 1 - 10 of 14
No Thumbnail Available
Publication

Investigación Clínica en tiempos de COVID-19

2020 , María Alicia Mordojovich , Gabriel Cavada , Andrés Maturana , LAVADOS GERMAIN, PABLO MANUEL

View
No Thumbnail Available
Publication

Enfoque traslacional a través de prácticas que potencian en diálogo y la reflexión en un lenguaje interdisciplinario.

2016 , LEPPE ZAMORA, JAIME ESTEBAN , MATURANA PEREA, ANDRES , CABIESES VALDES, BALTICA BEATRIZ , Margarita Bernales , Ana Castro , Romina Hidalgo , Nancy Pérez , OBACH KING, ALEXANDRA ALICE , LAPORT NICKOLAS

View
No Thumbnail Available
Publication

Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India

2006-07-01 , Kumar, Manoj , Birch, Stephen , MATURANA PEREA, ANDRES , Gafni, Amiran

Objective: With prevalence of HIV rising in pregnant women in India, pediatric HIV/AIDS is emerging as a public health problem. We evaluated the additional costs to the health care system and the additional health outcomes of introducing a voluntary primary care HIV screening program for pregnant women in India. Methods: The analysis was conducted from the government perspective. We analyzed two scenarios: a programme of universal screening nation-wide and a programme of screening restricted to high prevalence states. Health benefits were measured by the number of perinatal HIV cases prevented and the reduction in the potential years of life lost (PYLL). Findings: Nation-wide screening would cost the government Rs. 254.78 million and would prevent 9880 cases of perinatal HIV resulting in savings of 131,700 life years (average cost per HIV case prevented Rs. 25,787; per year reduction in PYLLs Rs. 1935). Implementing the program in only the high prevalence states would achieve 45% of these reductions in cases and life years lost at only 20% of this cost, at an average of Rs. 12,091 per HIV case prevented or Rs. 907 per year reduction in PYLLs (44 Indian rupees = US$ 1). In sensitivity analysis, the cost of the program was influenced mainly by antenatal coverage, the cost of the HIV test, the lifetime costs of treatment of a HIV infected child and the overhead costs. Conclusions: We provide an estimate of the additional costs and health effects of two approaches to introducing HIV screening among pregnant women in India. Decision-makers would have to demonstrate that the resources used for its implementation would result in more health benefits than from the alternative uses of those resources. © 2005 Elsevier Ireland Ltd. All rights reserved.

View
No Thumbnail Available
Publication

Animal-Derived Surfactants Versus Past and Current Synthetic Surfactants: Current Status

2007-03-01 , Moya, Fernando , MATURANA PEREA, ANDRES

In this review, the authors assess major outcomes resulting from head-to-head comparison trials of animal-derived surfactants with previous and newer synthetic surfactants and among them. They also pay special attention to issues of study design and quality of the trials reviewed. Animal-derived surfactants that contain surfactant proteins (Survanta, Infasurf, and Curosurf) perform clinically better than Exosurf, a synthetic surfactant containing only phospholipids, primarily in outcomes related to acute management of respiratory distress syndrome (RDS; faster weaning and pneumothorax) but not in overall mortality or incidence of bronchopulmonary dysplasia (BPD). Trials comparing various animal-derived surfactants that provide different amounts of surface protein B (SP-B) or phospholipids have shown minor differences in outcomes related to the management of RDS or none at all. The exception is the suggestion of better survival using a high initial dose of Curosurf when compared with Survanta. This observation is based on analysis of trials of relatively lesser quality that have included a smaller number of infants than other surfactant comparisons, however. Data from recent trials comparing a new-generation synthetic surfactant that contains a peptide mimicking the action of SP-B, Surfaxin, have shown that it performs better than Exosurf (faster weaning and less BPD) and at least as well as the animal-derived surfactants Survanta and Curosurf. The ideal surfactant comparison trial to demonstrate which surfactant is better has yet to be conducted. Future surfactant comparison trials should pay particular attention to study design, be appropriately sized, and include long-term follow-up. © 2007 Elsevier Inc. All rights reserved.

View
No Thumbnail Available
Publication

Bombas de infusión continua de jeringa en unidades neonatales

2011 , NADIA SCHMIDT S , CLAUDIA SÁEZ H , MATURANA PEREA, ANDRES

View
No Thumbnail Available
Publication

Association of Cow's Milk Protein Allergy Prevalence With Socioeconomic Status in a Cohort of Chilean Infants

2020 , María E. Arancibia , LUCERO, YALDA , Isabel Miquel , Pamela Marchant , Lorena Rodriguez , Francisco Alliende , Gloria Ríos , MATURANA PEREA, ANDRES

View
No Thumbnail Available
Publication

Medicina Basada en Evidencia: ¿podemos confiar en los resultados de los estudios clínicos aleatorizados bien diseñados?

2014 , MATURANA PEREA, ANDRES , Carla Benagli

View
No Thumbnail Available
Publication

Investigación traslacional en salud: un camino para la investigación pragmática e interdisciplinaria

2015 , Margarita Bernales , CABIESES VALDES, BALTICA BEATRIZ , MATURANA PEREA, ANDRES , OBACH KING, ALEXANDRA ALICE

View
No Thumbnail Available
Publication

Prevalencia de patología oftalmológica en prematuros menores de un año de edad

2012 , Juan Pablo López G , Diego Osandón V , Oliver Denk V , Ricardo Stevenon A , Ricardo Agurto R , Andrés Uauy N , Ricardo Salinas G , Marcela Pérez R , Horacio Cox M , MATURANA PEREA, ANDRES , Soledad Elías A

View
No Thumbnail Available
Publication

Comparison between Ages & Stages Questionnaire and Bayley Scales, to predict cognitive delay in school age

2020 , SCHONHAUT, LUISA , Marcela Pérez , Iván Armijo , MATURANA PEREA, ANDRES

View